Scroll to learn more
Restore recycling capability of cells
Remove buildup of toxic protein
Recover patient wellbeing
Our Science
KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance a second generation of compounds that cross the blood-brain barrier, selectively target kinases to restore autophagy, and remove the build-up of toxic proteins to recover patient well-being.
These compounds have the potential to provide new therapeutic options for patients suffering from neurodegenerative and immune diseases.
Our Pipeline
KeifeRx is advancing second generation kinase inhibitors targeting neurodegenerative diseases including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease and dementia (PDD) and frontotemporal dementia. Additionally, KeifeRx is targeting inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria.
KeifeRx In The News
June 10, 2025
EIN Presswire
KeifeRx Announces Expansion of Scientific Advisory Board
MAR 27, 2024
BUSINESSWIRE
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors